Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2002-05-17
2004-06-01
Hartley, Michael G. (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S482000, C424S185100, C514S089000, C514S416000, C514S384000, C514S172000, C514S174000
Reexamination Certificate
active
06743414
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form. The invention also relates to pharmaceutical inhalation compositions suitable for the treatment and prevention of bone diseases.
BACKGROUND OF THE INVENTION
Bisphosphonates are known in the art as bone resorption inhibitors. Examples of bisphosphonates include, alendronate, 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid; tiludronate, 4-chlorophenylthiomethylene bisphosphonatic acid; pamidronate, (3-amino-hydroxypropylidnen) bisphosphonic acid; etidronate, (1-hydroxyethylidene)bisphosphonic acid; residronate, 1-hydroxy-2-(3-pyridinyl)ethylidene bisphosphonic acid; zoledronate, 2-(imidazol-1-yl)-1-hydroxyethane-1,1-bisphosphonic acid; and the pharmaceutically acceptable salts of the above compounds.
Bisphosphonates, and their pharmaceutically acceptable salts, are useful in the treatment and prevention of bone diseases such as osteoporosis. Specifically, bisphosphonates are useful for the treatment of urolithiasis and are capable of inhibiting bone reabsorption. Bisphosphonates are also useful in lessening the risk of non-vertebral fractures in osteoporotic women and as a therapeutic agent for hypercalcemia and Paget's disease.
Current treatments for the above conditions comprise administration of a pharmaceutically effective amount of a bisphosphonic acid in oral dosage forms such as tablets. Bisphosphonates may also be administered by intravenous methods. The benefits of bisphosphonates are observed by its effect on bone mass and density. However oral and intravenous dosage forms have very low bioavailability. In some instances, the bioavailability is less than 1%. Accordingly, it would be desirable to find a route of administration of bisphosphonates that substantially increases its bioavailability.
In addition, oral dosage forms of the free acid form of certain bisphosphonates, e.g. 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, may result in gastric irritability, and therefore it would also be desirable to administer these bisphosphonates by a route that avoids such gastrointestinal problems.
REFERENCES:
patent: 5183815 (1993-02-01), Saari et al.
patent: 5661174 (1997-08-01), Naumann et al.
patent: 6143326 (2000-11-01), Mockel et al.
patent: 6414006 (2002-07-01), Harada et al.
patent: 6482411 (2002-11-01), Ahuja et al.
patent: WO 0000182 (2000-01-01), None
Physicians' Desk Reference, Drug Information on Fosamax® (Merck), 1995. (obtained through on-line PDR).*
The Bantam Medical Dictionary, (Laurence Urdang Associates Ltd.), 1982, pp. 212 and 358.*
Remington: The Practice of Science and Pharmacy, 19thedition, Chapt. 41, pp. 710-712 (1995).
J. L. McGuire (editor), Pharmaceuticals, vol. 4, pp. 2084-2085 (2000).
Geneva Pharmaceuticals Inc.
Haghighatian M.
Hartley Michael G.
McNally Lydia T.
LandOfFree
Inhalation administration of biophosphonates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhalation administration of biophosphonates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhalation administration of biophosphonates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3339861